375 related articles for article (PubMed ID: 25563824)
1. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
[TBL] [Abstract][Full Text] [Related]
2. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
Trendowski M; Christen TD; Acquafondata C; Fondy TP
BMC Cancer; 2015 Sep; 15():632. PubMed ID: 26357852
[TBL] [Abstract][Full Text] [Related]
3. Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo.
Trendowski M; Wong V; Wellington K; Hatfield S; Fondy TP
In Vivo; 2014; 28(6):1021-31. PubMed ID: 25398795
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.
Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
Invest New Drugs; 2015 Apr; 33(2):280-9. PubMed ID: 25560541
[TBL] [Abstract][Full Text] [Related]
5. Enlargement and multinucleation of u937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents.
Trendowski M; Wong V; Yu G; Fondy TP
Anticancer Res; 2015 Jan; 35(1):65-76. PubMed ID: 25550536
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
7. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.
Bousquet PF; Paulsen LA; Fondy C; Lipski KM; Loucy KJ; Fondy TP
Cancer Res; 1990 Mar; 50(5):1431-9. PubMed ID: 2302708
[TBL] [Abstract][Full Text] [Related]
8. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochalasins and colchicine on the accumulation and retention of daunomycin and vincristine in drug resistant tumor cells.
Tsuruo T; Iida H
Biochem Pharmacol; 1986 Apr; 35(7):1087-90. PubMed ID: 3457567
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of quinidine effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.
Parekh H; Chitnis M
Sel Cancer Ther; 1990; 6(2):93-102. PubMed ID: 2367755
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells.
Parekh HK; Mansuri-Torshizi H; Srivastava TS; Chitnis MP
Cancer Lett; 1992 Jan; 61(2):147-56. PubMed ID: 1730138
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
15. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.
Pierré A; Dunn TA; Kraus-Berthier L; Léonce S; Saint-Dizier D; Régnier G; Dhainaut A; Berlion M; Bizzari JP; Atassi G
Invest New Drugs; 1992 Aug; 10(3):137-48. PubMed ID: 1428723
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
19. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.
Wilkoff LJ; Dulmadge DA; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1989; 23(3):145-50. PubMed ID: 2924372
[TBL] [Abstract][Full Text] [Related]
20. Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.
Trendowski M; Zoino JN; Christen TD; Acquafondata C; Fondy TP
Transl Oncol; 2015 Aug; 8(4):308-17. PubMed ID: 26310377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
